Product Name: Butorphanol Tartrate
Chemical Name: (±)-17-(Cyclobutylmethyl)morphinan-3,14-diol tartrate
CAS Number: 58756-22-2
Manufacturing Company: [Manufacturer Name]
Recommended Uses: Pharmaceutical intermediate, veterinary and human medicine analgesic
Contact Information: [Supplier Address and Emergency Contact Number]
Synonyms: Butorphanol Tartrate, Stadol
Relevant Identified Uses: Pain management, research, veterinary medicine
Classification: Acute Toxicity (oral, dermal, inhalation), Skin Sensitizer, Specific Target Organ Toxicity
Signal Word: Danger
Hazard Statements: Harmful if swallowed. Causes respiratory depression. May cause irritation to skin, eyes, and respiratory tract. Can cause drowsiness or dizziness. Potential for severe overdose effects including CNS depression, coma, or death.
Precautionary Statements: Avoid contact with skin and eyes. Do not inhale dust or vapors. Use only in well-ventilated areas. Keep away from children and untrained users.
Symbol: Skull and Crossbones (Toxic), Exclamation mark (Irritant), Health hazard (Systemic effects)
Chemical Identity: Butorphanol Tartrate
Concentration: 100% pure substance (for analytical/research use), diluted or prepared solutions as per supplier specification
Other Ingredients: None in original pharmaceutical-grade powder; for formulations, refer to product labeling
Impurities: Trace organic solvents, residual water possible (batch dependent)
Molecular Formula: C21H29NO2·C4H6O6
Molecular Weight: 477.55 g/mol
General Advice: Seek medical attention immediately for any overdose, adverse reaction, or exposure beyond prescribed therapeutic use.
Inhalation: Move person to fresh air. If breathing is difficult, provide oxygen. If not breathing, give artificial respiration. Seek medical aid.
Skin Contact: Remove contaminated clothing. Wash affected area with plenty of soap and water. Seek medical advice if symptoms persist.
Eye Contact: Rinse cautiously with water for at least 15 minutes. Remove contact lenses if present and easy to do so. Consult an ophthalmologist.
Ingestion: Do not induce vomiting. Rinse mouth thoroughly with water. Seek immediate medical help. Provide this datasheet and any available substance packaging to healthcare professionals.
Other Symptoms: Monitor for respiratory distress, CNS depression (confusion, dizziness, impaired coordination), excessive drowsiness or pinpoint pupils.
Suitable Extinguishing Media: Use small foam, dry chemical extinguisher, carbon dioxide, or water spray. Do not use high volume water jet.
Hazards from Combustion: Toxic fumes are possible, including nitrogen oxides, carbon monoxide, carbon dioxide.
Protective Equipment: Firefighters should wear full protective gear including self-contained breathing apparatus.
Other Firefighting Advice: Move containers from area if it can be done safely. Avoid breathing fumes. Contain run-off and prevent entry to drains or watercourses due to toxicity. Avoid direct contact with released product.
Personal Precautions: Evacuate unnecessary personnel. Use proper personal protective equipment: gloves, lab coat, safety goggles, NIOSH-approved respirator if dust or aerosols form.
Environmental Precautions: Prevent further leakage or spillage. Do not allow material to contaminate soil, surface water, sewer, or drains.
Cleanup Methods: Collect using non-sparking tools and inert material (vermiculite, sand). Minimize dust generation. Place in tightly closed, labeled containers for disposal according to regulations.
Decontamination: Wash spill area with soap and water after recovery of material.
Reporting: Report spill to environmental authorities if required by regulatory thresholds.
Precautions for Safe Handling: Avoid dust generation and inhalation. Avoid contact with skin, eyes, and clothing. Wash hands thoroughly after handling. Handle with care, avoid situations leading to accidental self-injection or ingestion.
Technical Measures: Use proper engineering controls (fume hood, containment devices), follow established pharmaceutical handling policies.
Storage Conditions: Store in a tightly closed original container, away from light, moisture, and sources of heat or ignition. Keep in a secure area with access limited to trained personnel.
Compatibility: Avoid oxidizing agents. Keep away from food and beverages.
Long-Term Storage: Recommended temperature: 2-8°C (Refrigerated); check stability information for specific batch details.
Exposure Limits: No OSHA PEL/TLV established. Handle as a potent opioid; keep exposures as low as possible.
Engineering Controls: Use process enclosures, local exhaust ventilation, and/or other engineering controls to keep airborne levels below recommended exposure limits.
Protective Equipment: Wear chemical-resistant gloves (nitrile preferred), safety goggles or face shield, laboratory coat, and disposable respirator (N95/P100) if powder or aerosol risk present.
Hygiene Measures: Do not eat, drink, or smoke in work area. Wash hands before breaks and after use. Remove and clean contaminated clothing before reuse.
Environmental Exposure: Avoid release to environment, do not pour product down the drain or dispose with common laboratory waste.
Appearance: White or almost white crystalline powder
Odor: Odorless or slight odor
Odor Threshold: Not available
pH: 4–5 (1% solution in water, as tartaric acid salt)
Melting Point/Freezing Point: 218–220°C (decomposes)
Boiling Point: Not applicable (decomposes before boiling)
Flash Point: Not determined
Evaporation Rate: Not applicable
Flammability: May be combustible at high temperature
Upper/Lower Flammability or Explosive Limits: Not determined
Vapor Pressure: Not available
Vapor Density: Not available
Relative Density: Not available
Solubility: Soluble in water, slightly soluble in ethanol
Partition Coefficient (n-octanol/water): Not available
Auto-ignition Temperature: Not available
Decomposition Temperature: 218–220°C
Viscosity: Not applicable
Chemical Stability: Stable under recommended storage conditions.
Reactivity: No hazardous reactions with common pharmaceutical excipients under normal conditions.
Conditions to Avoid: Elevated temperatures, exposure to strong light or moisture, incompatible materials (strong oxidizers).
Hazardous Decomposition: Carbon oxides, nitrogen oxides, possibly tar and other organic vapors upon combustion or thermal decomposition.
Polymerization: Will not occur under normal laboratory conditions.
Route of Exposure: Inhalation, ingestion, skin, and eye contact
Acute Toxicity: LD50 (oral, rat): 50 mg/kg (literature), LD50 (IV, rat): 3.4 mg/kg
Chronic Toxicity: Prolonged or repeated exposure may cause opioid dependence, withdrawal symptoms, organ toxicity (liver, kidneys)
Symptoms: Respiratory depression, sedation, dizziness, nausea, vomiting, constipation, miosis, hypotension, euphoria or dysphoria, ataxia
Other Effects: Risk of fatal overdose especially with other CNS depressants; abuse potential exists; caution for use in pregnant or nursing women due to risk of neonatal opioid withdrawal syndrome
Sensitization: May cause allergic skin reactions
Mutagenicity/Carcinogenicity: No adequate data available from animal or human studies. No clear evidence of carcinogenic potential.
Reproductive Toxicity: Animal studies indicate adverse effects on fetal development at high doses.
Ecotoxicity: Toxic to aquatic organisms. Avoid uncontrolled environmental release.
Persistence and Degradability: Limited data; probable low environmental persistence due to possible biodegradation in water or soil.
Bioaccumulation Potential: No data, but structurally similar compounds show minimal bioaccumulation.
Mobility in Soil: Likely to be mobile based on solubility, may enter ground water if released.
Other Adverse Effects: Low doses can impact aquatic life and may bio-transform through sewage treatment; risk to sewage workers or aquatic organisms if not disposed properly.
Waste Treatment Methods: Dispose of via incineration in accordance with federal, state, and local regulations. Use a licensed pharmaceutical waste disposal contractor.
Contaminated Packaging: Treat as hazardous waste; triple rinse and decontaminate before disposal, then follow approved hazardous material protocols.
Disposal Precautions: Do not dispose of down the drain, in household trash, or as general laboratory waste. Avoid release to agricultural land or surface water.
Other Considerations: Consult local environmental and safety authorities to verify appropriate procedure based on quantity and specific circumstances.
UN Number: UN3249 (Medicines, toxic, solid, n.o.s. [Butorphanol])
UN Proper Shipping Name: Medicine, toxic, solid, n.o.s. (Butorphanol Tartrate)
Transport Hazard Class: 6.1 (Toxic substances)
Packing Group: III
Marine Pollutant: Classified as marine pollutant due to toxicity to aquatic organisms
Special Provisions: Secure packaging, limited access, clear signage according to IATA/IMDG/DOT/ADR guidelines; must be accompanied by SDS during transport.
Other Notes: Subject to controlled substance regulations in many countries—shipment requires special permits, documentation, and secure handling.
US Federal Regulations: Controlled Substance Schedule IV (DEA). SARA Title III Sections 302/313—Not listed. TSCA—Not listed.
European Union Regulations: Included as a controlled narcotic under Directive 2001/83/EC, Schedule III/IV. Classification according to CLP Regulation—Acute toxicity, category 3.
Canadian Regulations: Listed under Controlled Drugs and Substances Act; prescription required.
Global Inventories: Not listed on general chemical inventories, only available for controlled medicinal and research uses.
Workplace Control: Occupational use restricted to authorized users with specialized training and facilities.
Labeling Requirements: Use GHS-compliant labeling including hazard pictograms, hazard and precautionary statements, and signal word.
Providing high-quality chemical products and logistics solutions for global trade partners.
